Novo Nordisk Addresses FDA Concerns with Action Plan
Novo Nordisk received a warning letter from the FDA regarding an inspection at its New Jersey site in early 2025. The company has initiated a corrective action plan, continuously updating the FDA. Despite a second letter concerning another site, Novo remains confident there will be no impact on production.